dr. Sarah Raevens (MD)
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the second leading cause of cancer-related mortality worldwide. It generally develops on a background of chronic liver disease/liver cirrhosis. Liver cirrhosis and associated portal hypertension may be accompanied by pulmonary vascular complications, including hepatopulmonary syndrome and portopulmonary hypertension. Our research project focuses on these 2 entities, and includes both clinical and basic science research. Firstly, in a multicenter study we explore the prevalence, characteristics and outcome of patients with either hepatopulmonary syndrome or portopulmonary hypertension, in which also the relationship with HCC is studied. Secondly, we perform experimental basic research in which the pathogenic mechanisms contributing to hepatopulmonary syndrome development in liver cirrhosis are investigated, with specific focus on angiogenesis and inflammation.
- 'Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.' Oncotarget, 2016. (PMID: 27167000)
- 'Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma.' BMC Cancer, 2016. (PMID: 26753564)
- 'Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure.' Oncotarget, 2015. (PMID: 26293671
University Hospital Ghent, Hepatology Research Unit, Corneel Heymanslaan 10, Building B, second floor, 9000 Ghent